IDEAYA Launches Phase 1/2 IDE892 Trial in MTAP-Deleted Pancreatic and Lung Cancers
IDYA•IDEAYA Biosciences has enrolled the first patient in its Phase 1/2 trial evaluating IDE892 combined with IDE397 in MTAP-deleted pancreatic and non-small cell lung cancers. IDE892 exhibits a CYP3A4 IC50 above 45 μM, shows no time-dependent inhibition of seven major cytochromes, and has cleared multiple monotherapy dose cohorts without reaching MTD.
1. Trial Initiation
IDEAYA Biosciences has begun enrolling patients in its combined Phase 1/2 study of IDE892 and IDE397 targeting MTAP-deleted pancreatic ductal adenocarcinoma and non-small cell lung cancer, marking the first clinical evaluation of this dual synthetic lethal therapy.
2. Drug Profile and Pharmacokinetics
IDE892 demonstrates drug-like properties with a CYP3A4 IC50 above 45 micromolar and no time-dependent inhibition across seven major cytochrome P450 enzymes, with monotherapy dose escalation clearing multiple cohorts without reaching a maximum tolerated dose.
3. Preclinical Efficacy and Rationale
Preclinical studies of IDE892 combined with IDE397 yielded potent anti-tumor activity in MTAP-deleted models, achieving complete and durable responses at well-tolerated doses below monotherapy thresholds, leveraging over 1,400-fold selectivity for MTA-PRMT5 binding.
4. Development Timeline and Collaborations
Monotherapy expansion is expected in Q3 2026, and IDEAYA has partnered with Roche to test IDE892 alongside a pan-RAS inhibitor in MTAP-deleted pancreatic cancer, while advancing a CDKN2A-targeted program toward an IND filing in the first half of 2027.
